Inhibitors of fatty acid uptake and methods of use
The present disclosure describes inhibitors of fatty acid uptake and methods of using such inhibitors. Specifically, the present disclosure describes inhibitors with specificity for FATP2.
1. A method of inhibiting fatty acid uptake by cells, comprising:
contacting said cells with a compound of Formula (IV):
or a pharmaceutically acceptable salt form thereof, wherein:
R 1 and R 2 are independently selected from the group consisting of: H, F, Cl, Br, I, OH, and O(C 1-6 alkyl).
2. The method of claim 1 , wherein said cells are selected from the group consisting of intestinal epithelial cells and hepatocytes.
3. The method of claim 1 , wherein R 1 is selected from H and OH.
4. The method of claim 1 , wherein R 2 is selected from H and Br.
5. The method of claim 1 , wherein a compound of Formula (IV) is selected from the group consisting of:
or a pharmaceutically acceptable salt form thereof.
6. A method of inhibiting fatty acid uptake by cells, comprising:
contacting said cells with a compound selected from the group consisting of:
or a pharmaceutically acceptable salt form thereof.
7. The method of claim 6 , wherein said cells are selected from the group consisting of intestinal epithelial cells and hepatocytes.
8. A method of treating a disease associated with dyslipidemias and lipotoxicity in an individual in need thereof, comprising: administering, to the individual, a compound of Formula (IV):
or a pharmaceutically acceptable salt form thereof, wherein:
R 1 and R 2 are independently selected from the group consisting of: H, F, Cl, Br, I, OH, and O(C 1-6 alkyl).
9. The method of claim 8 , wherein said disease is selected from the group consisting of obesity, metabolic syndrome, insulin resistant diabetes, cardiovascular disease, and non-alcoholic fatty liver disease.
10. A method of treating a disease associated with dyslipidemias and lipotoxicity in an individual in need thereof, comprising:
Administering, to the individual, a compound selected from the group consisting of:
or a pharmaceutically acceptable salt form thereof.
11. The method of claim 10 , wherein said disease is selected from the group consisting of obesity, metabolic syndrome, insulin resistant diabetes, cardiovascular disease, and non-alcoholic fatty liver disease.
12. A method of inhibiting FATP2 in a cell, the method comprising:
contacting said cell with a compound of Formula (IV):
or a pharmaceutically acceptable salt form thereof, wherein:
R 1 and R 2 are independently selected from the group consisting of: H, F, Cl, Br, I, OH, and O(C 1-6 alkyl).
13. The method of claim 12 , wherein said cell is selected from the group consisting of intestinal epithelial cells and hepatocytes.
14. The method of claim 12 , wherein R 1 is selected from H and OH.
15. The method of claim 12 , wherein R 2 is selected from H and Br.
16. The method of claim 12 , wherein a compound of Formula (IV) is selected from the group consisting of:
or a pharmaceutically acceptable salt form thereof.
17. The method of claim 12 , wherein said contacting is in vitro.